Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Tumor Biology
Erschienen in: Tumor Biology 2/2014

01.02.2014 | Review

The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms

verfasst von: Leonardo Vinícius Monteiro de Assis, Mauro César Isoldi

Erschienen in: Tumor Biology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The malignant mesothelioma is an aggressive form of cancer with a mean survival rate of less than a year. Moreover, environmental exposure to minerals is an important factor in the development of malignant mesothelioma (MM), especially the mineral asbestos, which has a well-documented role in MM, and more recently, the mineral erionite has been proven to be a strong carcinogenic inducer of MM. In addition, the virus simian virus 40 has been implicated as a co-carcinogenic player in MM. However, the molecular mechanisms involved in the pathogenesis of this cancer are still not fully understood. Indeed, it is known that several genes are altered or mutated in MM, among those are p16INK4A, p14ARF, and neurofibromatosis type II. Furthermore, TP53 has been reported to be mutated in the majority of the cancers; however, in MM, it is very uncommon mutations in this gene. Also, the PTEN gene has been shown to play an important role in endometrial cancer and glioblastoma, although the role of PTEN in MM has yet to be established. Taken altogether, this review focuses on the historical aspects, molecular mechanisms, interaction with other genes and proteins, and the role of these genes in MM. Lastly, this review questions the cancer theory of the two hits because the functions of both PTEN and TP53 are not fully explained by this theory.
Literatur
1.
2.
3.
van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23(28):6881–9.PubMed
4.
5.
ATSDR. Public health statement—asbestos. Atlanta: Agency for Toxic and Disease Registry; 2001.
6.
7.
Eom M, Abdul-Ghafar J, Park SMHJ, Hong SW, Kwon KY, Ko ES, et al. No detection of simian virus 40 in malignant mesothelioma in Korea. Korean J Pathol. 2013;47(2):124–9.PubMedCentralPubMed
8.
Qi F, Carbone M, Yang H, Gaudino G. Simian virus 40 transformation, malignant mesothelioma and brain tumors. Expert Rev Respir Med. 2013;5(5):683–97. doi:10.​1586/​ers.​11.​51.
9.
10.
Kroczynska B, Cutrone R, Bocchetta M, Yang H, Elmishad AG, Vacek P, et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci. 2006;103(38):14128–33. doi:10.​1073/​pnas.​0604544103.PubMed
11.
Manfredi JJ, Dong J, Liu W-J, Resnick-Silverman L, Qiao R, Chahinian P, et al. Evidence against a role for SV40 in human mesothelioma. Cancer Res. 2005;65(7):2602–9.PubMed
12.
13.
Jean D, Daubriac J, Le Pimpec-Barthes F, Galateau-Salle F, Jaurand M-C. Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch Pathol Lab Med. 2012;136(3):277–93. doi:10.​5858/​arpa.​2011-0215-RA.PubMed
14.
Hu Q, Akatsuka S, Yamashita Y, Ohara H, Nagai H, Okazaki Y, et al. Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. Lab Investig. 2010;90(3):360–73.PubMed
15.
16.
Sekido Y, Pass HI, Bader S, Mew DJY, Christman MF, Gazdar AF, et al. Neurofibromatosis Type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55(6):1227–31.PubMed
17.
18.
Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, et al. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep. 2009;2(2):181–8.PubMed
19.
Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. 2005;24(40):6080–9. doi:10.​1038/​sj.​onc.​1208744.PubMed
20.
21.
Wilson SM, Barbone D, Yang T-M, Jablons DM, Bueno R, Sugarbaker DJ, et al. mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol. 2008;39(5):576–83. doi:10.​1165/​rcmb.​2007-0460OC.PubMed
22.
Agarwal V, Campbell A, Beaumont K, Cawkwell L, Lind M. PTEN protein expression in malignant pleural mesothelioma. Tumor Biol. 2012;34(2):847–51. doi:10.​1007/​s13277-012-0615-9.
23.
Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg. 2008;33(3):501–5. doi:10.​1016/​j.​ejcts.​2007.​09.​045.
24.
Frezza C, Martins CP. From tumor prevention to therapy: empowering p53 to fight back. Drug Resist Updat. 2012;15(5):258–67. Reviews and commentaries in antimicrobial and anticancer chemotherapy.PubMed
25.
26.
Freeman DJ, Li AG, Wei G, Li H-H, Kertesz N, Lesche R, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003;3(2):117–30. doi:10.​1016/​S1535-6108(03)00021-7.PubMed
27.
Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133(3):403–14.PubMed
28.
Heyn H, Carmona FJ, Gomez A, Ferreira HJ, Bell JT, Sayols S, et al. DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker. Carcinogenesis. 2013;34(1):102–8. doi:10.​1093/​carcin/​bgs321.PubMed
29.
30.
Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61(8):3225–9.PubMed
31.
32.
Hama R, Watanabe Y, Shinada K, Yamada Y, Ogata Y, Yoshida Y, et al. Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma. Tumor Biol. 2012;33(6):2031–40. doi:10.​1007/​s13277-012-0462-8.
33.
34.
35.
Hansen J, de Klerk NH, Musk AW, Hobbs MS. Environmental exposure to crocidolite and mesothelioma: exposure-response relationships. Am J Respir Crit Care Med. 1998;157(1):69–75.PubMed
36.
Luo S, Liu X, Mu S, Tsai SP, Wen CP. Asbestos related diseases from environmental exposure to crocidolite in Da-yao, China. I. Review of exposure and epidemiological data. Occup Environ Med. 2003;60(1):35–42. doi:10.​1136/​oem.​60.​1.​35.PubMed
37.
Powers A, Carbone M. The role of environmental carcinogens, viruses and genetic predisposition in the pathogenesis of mesothelioma. Cancer Biol Ther. 2002;1(4):348–53.PubMed
38.
39.
Pedra F, Tambellini AT, Pereira BB, Carioca da Costa AC, Albuquerque de Castro H. Mesothelioma mortality in Brazil, 1980–2003. Int J Occup Environ Health. 2008;14(3):170–5.PubMed
40.
Roggli VL, Oury TD, Moffat EJ. Malignant mesothelioma in women. Anat Pathol. 1997;2:147–63.PubMed
41.
Price B, Ware A. Mesothelioma trends in the United States: an update based on surveillance, epidemiology, and end results program data for 1973 through 2003. Am J Epidemiol. 2004;159(2):107–12. doi:10.​1093/​aje/​kwh025.PubMed
42.
43.
Magnani C, Agudo A, Gonzalez CA, Andrion A, Calleja A, Chellini E, et al. Multicentric study on malignant pleural mesothelioma and non-occupational exposure to asbestos. Br J Cancer. 2000;83(1):104–11.PubMedCentralPubMed
44.
Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, et al. TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci. 2006;103(27):10397–402. doi:10.​1073/​pnas.​0604008103.PubMed
45.
46.
47.
Xu A, Zhou H, Yu DZ, Hei TK. Mechanisms of the genotoxicity of crocidolite asbestos in mammalian cells: implication from mutation patterns induced by reactive oxygen species. Environ Health Perspect. 2002;110(10):1003–8.PubMedCentralPubMed
48.
Weiner S, Neragi-Miandoab S. Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors. J Carcinog. 2008;7(1):3.PubMedCentralPubMed
49.
50.
Tweedale G. Asbestos and its lethal legacy. Nat Rev Cancer. 2002;2(4):311–4.PubMed
51.
52.
53.
Ben David Y, Prideaux VR, Chow V, Benchimol S, Berstein A. Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus. Oncogene. 1988;3(2):179–85.PubMed
54.
55.
Mowat M, Cheng A, Kimura N, Bernstein A, Benchimol S. Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus. Nature. 1985;314(6012):633–6.PubMed
56.
Vogelstein B, Lane D. Surfing the p53 network. Nature. 2000;408(6810):307.PubMed
57.
Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348(6303):747–9. doi:10.​1038/​348747a0.PubMed
58.
Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci. 1992;89(10):4495–9.PubMed
59.
Yonish-Rouach E, Resnftzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991;352(6333):345.PubMed
60.
Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445(7128):661.PubMed
61.
Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656.PubMed
62.
Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer. 2009;9(10):724–37.PubMed
63.
64.
Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993;362(6423):857–60.PubMed
65.
Chène P. Inhibiting the p53–MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer. 2003;3(2):102.PubMed
66.
67.
Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther. 2005;16(9):16–27.
68.
Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, Pelin K, et al. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res. 1992;52(9):2610–5.PubMed
69.
70.
Vivo C, Lecomte C, Levy F, Leroy K, Kirova Y, Renier A, et al. Cell cycle checkpoint status in human malignant mesothelioma cell lines: response to gamma radiation. Br J Cancer. 2003;88(3):388–95.PubMedCentralPubMed
71.
72.
Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15(4):356–62.PubMed
73.
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943–7.PubMed
74.
Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283–96.PubMed
75.
76.
Cristofano AD, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet. 1998;19(4):348–55. doi:10.​1038/​1235.PubMed
77.
Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, Barrantes IDB. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol. 1998;8(21):1169–78.PubMed
78.
Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Robert L, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci. 1998;95(9):5246–50.PubMed
79.
Lachyankar MB, Sultana N, Schonhoff CM, Mitra P, Poluha W, Lambert S, et al. A role for nuclear PTEN in neuronal differentiation. J Neurosci. 2000;20(4):1404–13.PubMed
80.
Ginn-Pease ME, Eng C. Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7 Cells. Cancer Res. 2003;63(2):282–6.PubMed
81.
Déléris P, Bacqueville D, Gayral SP, Carrez L, Salles J-P, Perret B, et al. SHIP-2 and PTEN are expressed and active in vascular smooth muscle cell nuclei, but only SHIP-2 is associated with nuclear speckles. J Biol Chem. 2003;278(40):38884–91.PubMed
82.
Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003;1(3):e59.PubMedCentralPubMed
83.
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647–58.PubMed
84.
García JM, Silva J, Peña C, Garcia V, Rodríguez R, Cruz MA, et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosom Cancer. 2004;41(2):117–24. doi:10.​1002/​gcc.​20062.PubMed
85.
Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus: implications for PTEN stability to proteasome-mediated degradation. J Biol Chem. 2001;276(2):993–8. doi:10.​1074/​jbc.​M009134200.PubMed
86.
87.
Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, Downes CP. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. 2003;22(20):5501–10.PubMed
88.
Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5(8):671–88.PubMed
89.
Borders EB, Bivona C, Medina PJ. Mammalian target of rapamycin: biological function and target for novel anticancer agents. Am J Health Syst Pharm. 2010;67(24):2095–106. doi:10.​2146/​ajhp100020.PubMed
90.
Holmes D. PI3K pathway inhibitors approach junction. Nat Rev Drug Discov. 2011;10(8):563–4.PubMed
91.
92.
Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128(1):157–70.PubMed
93.
Chung J-H, Ostrowski MC, Romigh T, Minaguchi T, Waite KA, Eng C. The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation. Hum Mol Genet. 2006;15(17):2553–9. doi:10.​1093/​hmg/​ddl177.PubMed
94.
Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell. 2006;23(4):575–87.PubMed
95.
96.
Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of MDM2 from the cytoplasm to the nucleus. Proc Natl Acad Sci. 2001;98(20):11598–603. doi:10.​1073/​pnas.​181181198.PubMed
97.
98.
Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest. 2010;120(3):681–93. doi:10.​1172/​jci40535.PubMedCentralPubMed
99.
Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer. 2011;11(7):503–11. doi:10.​1038/​nrc3057.PubMed
100.
Tanaka M, Rosser CJ, Grossman HB. PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer. Cancer Detect Prev. 2005;29(2):170–4.PubMed
101.
Saito Y, Swanson X, Mhashilkar AM, Oida Y, Schrock R, Branch CD, et al. Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo. Gene Ther. 2003;10(23):1961–9.PubMed
102.
Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group study. J Clin Oncol. 2007;25(17):2406–13. doi:10.​1200/​jco.​2006.​09.​7634.PubMed
103.
Knudson AJ. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci. 1971;68(4):820–3.PubMed
104.
Fung YK, Murphree AL, T'Ang A, Qian J, Hinrichs SH, Benedict WF. Structural evidence for the authenticity of the human retinoblastoma gene. Science. 1987;236(4809):1657–61.PubMed
105.
Venkatachalam S, Shi Y-P, Jones SN, Vogel H, Bradley A, Pinkel D, et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 1998;17(16):4657–67.PubMed
106.
Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome—a molecular and clinical review. Br J Cancer. 1997;1997(76):1–14.
107.
Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet. 2010;42(5):454–8.PubMedCentralPubMed
108.
Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1996;111(4):815–26.PubMed
109.
Bölükbasa S, Manegold C, Eberlein M, Bergmann T, Fisseler-Eckhoff A, Schirren J. Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer. 2011;71(1):75–81. doi:10.​1016/​j.​lungcan.​2009.​08.​019.
110.
111.
112.
Hazarika M, White Jr RM, Booth BP, Wang YC, Ham DY, Liang CY, et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res. 2005;11(3):982.PubMed
113.
Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer. 2002;38(2):111–21 (Amsterdam, Netherlands).PubMed
114.
Fizazi K, Ducreux M, Ruffié P, Bonnay M, Daniel C, Soria J-C, et al. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. J Clin Oncol. 2000;18(11):2293–300.PubMed
115.
Fizazi K, Doubre H, Le Chevalier T, Riviere A, Viala J, Daniel C, et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol. 2003;21(2):349–54. doi:10.​1200/​jco.​2003.​05.​123.PubMed
116.
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–44. doi:10.​1200/​jco.​2003.​11.​136.PubMed
117.
Karrison T, Kindler HL, Gandara DR, Lu C, Guterz TL, Nichols K, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol. 2007;25(18):5. (Suppl 18S Abstract 7526):391s.
118.
Jänne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002;62(18):5242–7.PubMed
119.
Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the cancer and leukemia group B. Clin Cancer Res. 2005;11(6):2300–4. doi:10.​1158/​1078-0432.​ccr-04-1940.PubMed
120.
Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008;113(4):808–14. doi:10.​1002/​cncr.​23617.PubMed
121.
Rvd M, Robinson B, Nelson D. Gene therapy for malignant mesothelioma: beyond the infant years. Cancer Gene Ther. 2006;13(10):897–904.
122.
Lindsay Y, McCoull D, Davidson L, Leslie NR, Fairservice A, Gray A, et al. Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. J Cell Sci. 2006;119(24):5160–8. doi:10.​1242/​jcs.​000133.PubMed
Metadaten
Titel
The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms
verfasst von
Leonardo Vinícius Monteiro de Assis
Mauro César Isoldi
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1210-4

Weitere Artikel der Ausgabe 2/2014

Tumor Biology 2/2014 Zur Ausgabe

Research Article

High expression of MACC1 predicts poor prognosis in patients with osteosarcoma

Research Article

CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion

Research Article

Prognostic value of EpCAM/MUC1 mRNA-positive cells in non-small cell lung cancer patients

Research Article

miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway

Research Article

Association of CTLA4 gene polymorphism (rs5742909) with cervical cancer: a meta-analysis

Research Article

Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise